PLOUËT et al.

Appl. No. 10/566,679

Attny. Ref.: 1487-28

Amendment

September 29, 2008

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-11. (Cancelled)

Claim 12. (Canceled)

Claim 13. (Canceled)

Claim 14. (Canceled)

Claims 15-17. (Canceled)

Claim 18. (Canceled)

19. (new) A method for the treatment a pathology requiring inhibition of endothelial proliferation or endothelial activation,

said method comprising administering a pharmaceutically acceptable amount of a protein comprising the NOV protein fragment set forth in SEQ ID NO: 12 to a person in need of said treatment.

- 20. (New) The method according to claim 19, wherein said pathology requiring the inhibition of endothelial proliferation is age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis, angiomas or angiosarcomas.
- 21. (new) The method according to claim 19 wherein said pathology requiring the inhibition of endothelial proliferation is Castelman's disease or Kaposi's sarcoma.
- 22. (New) The method according to claim 19, wherein said pathology requiring the inhibition of endothelial activation is allograft rejection, xenograft rejection, acrocyanosis or scleroderma.

- 3 -

1387329

PLOUËT et al.

Appl. No. 10/566,679 Attny. Ref.: 1487-28

Amendment

September 29, 2008

- 23. (New) The method according to claim 19, wherein said protein consists of the NOV protein fragment set forth in SEQ ID NO: 12.
- 24. (New) A method for the treatment of cancer comprising administering a pharmaceutically acceptable amount of a protein comprising the NOV protein fragment set forth in SEQ ID NO: 12 to a person in need of said treatment.
- 25. (New) The method according to claim 24, wherein said protein consists of the NOV protein fragment set forth in SEQ ID NO: 12.
- 26. (New) The method of claim 19 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.
- 27. (New) The method of claim 20 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.
- 28. (New) The method of claim 21 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.
- 29. (New) The method of claim 22 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.
- 30. (New) The method of claim 23 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.
- 31. (New) The method of claim 24 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.
- 32. (New) The method of claim 25 wherein said pharmaceutical composition is administered at a rate of approximately 0.1 to approximately 20 mg/kg/day.